Short answer
ImmunityBio, Inc. (IBRX) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $44M (up 167.6% year over year) with net income of −$633M.
Q1 2026 key financials · XBRL
- Revenue
- $44M
- +167.6% YoY
- Net income
- −$633M
- −388.1% YoY
- Operating margin
- -157.9%
- EPS (diluted)
- −$0.62
- −313.3% YoY
Source: XBRL data from the ImmunityBio, Inc. (IBRX) Q1 2026 10-Q on SEC EDGAR. USD.
ImmunityBio, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Additional financing need; cash, cash equivalents and marketable securities totaled $380.9 million as of March 31, 2026
- $480.0 million related-party convertible promissory note held by an entity affiliated with Dr. Soon-Shiong
- TICE BCG supply shortage risk; ANKTIVA demand depends on the only FDA-approved U.S. BCG strain
- Commercialization risk; limited experience with sales, marketing and distribution after ANKTIVA’s April 2024 FDA approval
- Regulatory compliance risk; ongoing requirements could trigger penalties or significant additional expenses despite existing approvals
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ImmunityBio, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.